Jane Street Group LLC acquired a new position in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 48,812 shares of the company's stock, valued at approximately $83,000. Jane Street Group LLC owned approximately 0.12% of Vigil Neuroscience at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the business. Blair William & Co. IL purchased a new stake in Vigil Neuroscience in the fourth quarter valued at about $551,000. Renaissance Technologies LLC raised its position in shares of Vigil Neuroscience by 698.5% in the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company's stock valued at $624,000 after purchasing an additional 321,300 shares during the last quarter. abrdn plc raised its position in shares of Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after purchasing an additional 293,461 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in Vigil Neuroscience in the 4th quarter worth approximately $249,000. Finally, Marshall Wace LLP boosted its stake in Vigil Neuroscience by 85.3% in the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company's stock worth $454,000 after purchasing an additional 122,853 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on VIGL. Jefferies Financial Group cut shares of Vigil Neuroscience to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright lowered Vigil Neuroscience from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $14.00 to $8.00 in a research note on Tuesday, May 27th. Citizens Jmp downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Citigroup lowered Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Finally, Wedbush downgraded Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and decreased their target price for the stock from $13.00 to $8.00 in a report on Thursday, May 22nd. Ten equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Vigil Neuroscience has a consensus rating of "Hold" and an average price target of $10.80.
View Our Latest Report on Vigil Neuroscience
Vigil Neuroscience Stock Performance
Shares of NASDAQ VIGL opened at $7.88 on Monday. The firm has a fifty day moving average of $3.40 and a 200 day moving average of $2.61. The firm has a market cap of $367.78 million, a PE ratio of -3.83 and a beta of 3.43. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $7.95.
Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, equities analysts predict that Vigil Neuroscience, Inc. will post -2.07 EPS for the current fiscal year.
Vigil Neuroscience Company Profile
(
Free Report)
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Stories
Want to see what other hedge funds are holding VIGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vigil Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.
While Vigil Neuroscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
